Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
26
RAPP Quote, Financials, Valuation and Earnings
Last price:
$30.17
Seasonality move
:
-47.31%
Day range:
$28.99 - $30.74
52-week range:
$6.43 - $42.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.15x
Volume:
221.9K
Avg. volume:
407.8K
1-year change:
56.64%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$2.69
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RAPP
Rapport Therapeutics, Inc.
|
-- | -$0.78 | -- | -19.61% | $52.25 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BBOT
BridgeBio Oncology Therapeutics
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$198K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RAPP
Rapport Therapeutics, Inc.
|
$30.20 | $52.25 | $1.1B | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BBOT
BridgeBio Oncology Therapeutics
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RAPP
Rapport Therapeutics, Inc.
|
2.27% | 2.847 | 1.1% | 35.84x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BBOT
BridgeBio Oncology Therapeutics
|
-- | 0.000 | -- | -- |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RAPP
Rapport Therapeutics, Inc.
|
-$256K | -$30M | -28.33% | -28.91% | -- | -$17.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BBOT
BridgeBio Oncology Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
Rapport Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RAPP or AIM?
AIM ImmunoTech has a net margin of -- compared to Rapport Therapeutics, Inc.'s net margin of -10571.43%. Rapport Therapeutics, Inc.'s return on equity of -28.91% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital RAPPRapport Therapeutics, Inc.-- -$0.71 $523.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About RAPP or AIM?
Rapport Therapeutics, Inc. has a consensus price target of $52.25, signalling upside risk potential of 73.01%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Rapport Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Rapport Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAPPRapport Therapeutics, Inc.8 0 0 AIMAIM ImmunoTech1 0 0 -
Is RAPP or AIM More Risky?
Rapport Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock RAPP or AIM?
Rapport Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapport Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPP or AIM?
Rapport Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Rapport Therapeutics, Inc.'s net income of -$26.9M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Rapport Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapport Therapeutics, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPPRapport Therapeutics, Inc.-- -- -- -$26.9M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns RAPP or BBOT?
BridgeBio Oncology Therapeutics has a net margin of -- compared to Rapport Therapeutics, Inc.'s net margin of --. Rapport Therapeutics, Inc.'s return on equity of -28.91% beat BridgeBio Oncology Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RAPPRapport Therapeutics, Inc.-- -$0.71 $523.5M BBOTBridgeBio Oncology Therapeutics-- -- -- -
What do Analysts Say About RAPP or BBOT?
Rapport Therapeutics, Inc. has a consensus price target of $52.25, signalling upside risk potential of 73.01%. On the other hand BridgeBio Oncology Therapeutics has an analysts' consensus of -- which suggests that it could fall by --. Given that Rapport Therapeutics, Inc. has higher upside potential than BridgeBio Oncology Therapeutics, analysts believe Rapport Therapeutics, Inc. is more attractive than BridgeBio Oncology Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RAPPRapport Therapeutics, Inc.8 0 0 BBOTBridgeBio Oncology Therapeutics0 0 0 -
Is RAPP or BBOT More Risky?
Rapport Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BridgeBio Oncology Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RAPP or BBOT?
Rapport Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Oncology Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapport Therapeutics, Inc. pays -- of its earnings as a dividend. BridgeBio Oncology Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPP or BBOT?
Rapport Therapeutics, Inc. quarterly revenues are --, which are larger than BridgeBio Oncology Therapeutics quarterly revenues of --. Rapport Therapeutics, Inc.'s net income of -$26.9M is higher than BridgeBio Oncology Therapeutics's net income of --. Notably, Rapport Therapeutics, Inc.'s price-to-earnings ratio is -- while BridgeBio Oncology Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapport Therapeutics, Inc. is -- versus -- for BridgeBio Oncology Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPPRapport Therapeutics, Inc.-- -- -- -$26.9M BBOTBridgeBio Oncology Therapeutics-- -- -- --
-
Which has Higher Returns RAPP or CVM?
CEL-SCI Corp. has a net margin of -- compared to Rapport Therapeutics, Inc.'s net margin of --. Rapport Therapeutics, Inc.'s return on equity of -28.91% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital RAPPRapport Therapeutics, Inc.-- -$0.71 $523.5M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About RAPP or CVM?
Rapport Therapeutics, Inc. has a consensus price target of $52.25, signalling upside risk potential of 73.01%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Rapport Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Rapport Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAPPRapport Therapeutics, Inc.8 0 0 CVMCEL-SCI Corp.1 0 0 -
Is RAPP or CVM More Risky?
Rapport Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock RAPP or CVM?
Rapport Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapport Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPP or CVM?
Rapport Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Rapport Therapeutics, Inc.'s net income of -$26.9M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Rapport Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapport Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPPRapport Therapeutics, Inc.-- -- -- -$26.9M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns RAPP or IGC?
IGC Pharma, Inc. has a net margin of -- compared to Rapport Therapeutics, Inc.'s net margin of -953.4%. Rapport Therapeutics, Inc.'s return on equity of -28.91% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital RAPPRapport Therapeutics, Inc.-- -$0.71 $523.5M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About RAPP or IGC?
Rapport Therapeutics, Inc. has a consensus price target of $52.25, signalling upside risk potential of 73.01%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1192.1%. Given that IGC Pharma, Inc. has higher upside potential than Rapport Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Rapport Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAPPRapport Therapeutics, Inc.8 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is RAPP or IGC More Risky?
Rapport Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock RAPP or IGC?
Rapport Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rapport Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPP or IGC?
Rapport Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Rapport Therapeutics, Inc.'s net income of -$26.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Rapport Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapport Therapeutics, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPPRapport Therapeutics, Inc.-- -- -- -$26.9M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns RAPP or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Rapport Therapeutics, Inc.'s net margin of -255.85%. Rapport Therapeutics, Inc.'s return on equity of -28.91% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital RAPPRapport Therapeutics, Inc.-- -$0.71 $523.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About RAPP or NBY?
Rapport Therapeutics, Inc. has a consensus price target of $52.25, signalling upside risk potential of 73.01%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Rapport Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Rapport Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAPPRapport Therapeutics, Inc.8 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is RAPP or NBY More Risky?
Rapport Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock RAPP or NBY?
Rapport Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Rapport Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RAPP or NBY?
Rapport Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Rapport Therapeutics, Inc.'s net income of -$26.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Rapport Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rapport Therapeutics, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAPPRapport Therapeutics, Inc.-- -- -- -$26.9M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
